But unfortunately, it's incredibly difficult to reengineer the constrained peptides that we find in nature to become new drugs.

但不幸的是，要想重组界中的限制性肽，将其制成新药，是异常难的。

How do we define nature when we can reengineer its properties, and when should we do it?

当我们可以重新设计的属性时， 我们如何定义，么时候应该这样做？

I decided to reengineer the process through some classic business tools.

我决定通过一些经典的商业工具重新设计流程。